Fighting global pandemics with data

Shivom’s contribution to fighting the coronavirus pandemic.

The SARS-CoV2 virus is among us. We realized that only through global partnerships and communities that we will overcome this great threat to humanity.

In the current coronavirus outbreak, the global research community is mounting a large-scale public health response to understand the pathogen and combat the pandemic. Vast amounts of data` generated need analyzing in the context of pre-existing data and shared for solution-centric research approaches to combat the disease and inform public healthcare policies. However, research showed that the vast majority of clinical studies on COVID-19 do not meet proper quality standards due to small sample size. Our approach is designed to provide healthcare professionals with an urgently needed platform to find and analyze genetic data, and securely and anonymously share sensitive patient data to fight the disease outbreak.

As result of our efforts, Shivom was selected to be part of the World Economic Forum’s COVID19 program. Being part of the WEF global Covid-19 efforts means that Shivom will get direct access to the WEFs public-private partner’s network to help our Covid-19 solution scale. The WEF aims to find innovative solutions tackling the global pandemic from three angles:

1, Prevention & detection   2, Respond & deliver   3, Recover & rebuild

The WEF efforts are organized on UpLink, a digital platform to crowdsource innovations, in an effort to accelerate the delivery of the UN Sustainable Development Goals (SDGs).

We are thrilled to acknowled as part of the UpLink family. The UpLink community is building a community of like-minded and impact-driven changemakers, innovators and entrepreneurs from all over the world.

But our efforts did not end here. Our organization was also selected to be a member of the XPRIZE Pandemic Alliance. Most of you may have heard about XPRIZE before, a non-profit organization founded by Peter Diamandis that designs and hosts public competitions intended to encourage technological development to benefit humanity. Their Board of Trustees include James Cameron, Larry Page, Arianna Huffington, and Ratan Tata among others. The XPRIZE Pandemic Alliance is a global coalition that combines the power of collaboration, competition, shared innovation and radical thinking to accelerate solutions that can be applied to COVID-19 and future pandemics. As part of this Alliance, researchers and scientists are invited to share and access data through the XPRIZE Data Collaborative, a unique platform for researchers and innovators to collaborate, share and learn from data in a broad spectrum of fields in their search for solutions. This trove of data aims to unlock new approaches to fighting pandemics and will serve as the backbone to the collective effort that will prepare us for additional pandemic spikes like COVID-19, or other viral threats.

XPRIZE Founder and Executive Chairman Peter H. Diamandis: “The XPRIZE Pandemic Alliance will leverage data and human collaboration like never before to facilitate technological breakthroughs for the benefit of humankind.”

Shivom takes part of the XPRIZE Exchange, a digital collaboration platform, which facilitates matchmaking between partners so we can leverage the network of Alliance Partners to contribute their resources, data and expertise to drive the latest COVID-19 breakthroughs. One of the breakthroughs is certainly our pandemic preparedness solution that is hosted on our platform and free to use for all COVID-19 researchers.

Being a part of the precision medicine platform Shivom, we developed a versatile pandemic preparedness solution that allows healthcare professionals to rapidly share and analyze genetic data. The platform solves several problems of the global medical and research community, such as siloed data, cross-border data sharing, lack of state-of-the-art analytic tools, GDPR-compliance, and ease-of-use. The platform combines patient genomic & omics data sets, a marketplace for bioinformatics algorithms, new diagnostic tools, and data-sharing capabilities to advance virus epidemiology and biomarker discovery. The bioinformatics marketplace contains some preinstalled COVID-19 pipelines to analyze virus- and host genomes without the need for bioinformatics expertise. The platform will be the quickest way to rapidly gain insight into the association between virus-host interactions and COVID-19 in various populations which can have a significant impact on managing the current pandemic and potential future disease outbreaks. We prepared a paper on how to tackle COVID-19 and future outbreaks of the SARS-CoV2 or other viruses using our precision medicine platform. The preprint is available on medRxiv and Europe PMC.

Shivom

Data Flow in the Shivom platform. The user does not need in-depth bioinformatics expertise and is guided through all necessary steps from data upload to data analytics. Basically, data from a variety of sources is uploaded by the data custodian and data permission rules are set. If the data is set to open or monetizable, it will be searchable in the data marketplace. Once a dataset of interest is identified and filtered, the user can select a bioinformatic workflow (pipeline), configure user-specific parameters if needed, and then start the analysis. The user can then investigate and share the resulting report and, depending on the workflow, run further downstream analysis.

COVID-19 Call to action

The urgency of tackling COVID-19 has led governments in many countries to launch a number of short-notice and fast-tracked initiatives. Without proper coordination amongst ministries and agencies, they run the risk of duplicating efforts or missing opportunities, resulting in slower progress and research inefficiencies. The best way to prevent a further spread of the virus and potential new pandemics is to apply the same principles as we use to prevent catastrophic forest fires: survey aggressively for smaller brush fires and stomp them out immediately. We need to invest now in an integrated data surveillance architecture designed to identify new outbreaks at the very early stages and rapidly invoke highly targeted containment responses. Currently, our healthcare system is not set up for this. In this new surveillance architecture proposed in our paper, genomic analysis of patients presenting with severe clinical symptoms would be performed up front in hospital labs piggybacked on routine diagnostic testing.

Researchers can use the data in our data-hub to compare new cases with existing datasets. Using genomic sequencing, the novel causative agent could be identified within hours, and the network would instantaneously connect the patients presenting at multiple locations as part of the same incident, providing situational awareness of the scope and scale of the event. Using a globally accessible, easy-to-use solution that provides a ‘one-stop shop’ for the centralization of information on new virus-host interactions can help ensure that appropriate conditions for collaborative research and sharing of preliminary research findings and data are in place to reap their full benefits. Beyond short-term policy responses to COVID-19, incorporating data sharing with the Shivom platform into ongoing mission-oriented research and innovation policies could help tackle future pandemics on a national or international scale, for example to enhance datasets informativeness to reveal host infection dynamics for SARS-CoV-2 and therefore to improve medical treatment options for COVID-19 patients. In addition, it can help to determine and design optimal targets for therapeutics against SARS-CoV-2. In line with the recommendations by the Research Data Alliance (RDA) COVID-19 Working Group, the Shivom platform can be used for:

  • Sharing clinical data in a timely and trustworthy manner to maximize the impact of healthcare measures and clinical research during the emergency response
  • Encouraging people to publish their omics data alongside a paper
  • Underlining that epidemiology data underpin early response strategies and public health measures
  • Providing a platform to collect important social and behavioural data (as metadata) in all pandemic studies
  • Evidencing the importance of public data sharing capabilities alongside data analytics
  • Offering a general ecosystem to exploit relevant ethical frameworks relating to the collection, analysis and sharing of data in similar emergency situations

At this point in time, the research community should be clear that a second or third wave of the COVID-19 pandemic will hit most countries. In addition, other epidemics and global pandemics will follow; it is just a matter of time. We also encourage sharing data from COVID-19 and other virus outbreaks, including data from people who were exposed to the same pathogen but did not get the disease or possibly were infected but did not get symptoms.

Dr. Axel Schumacher, Co-Founder & CEO

About the author:
Dr. Schumacher is a geneticist, author, & futurologist and Co-Founder of Shivom. He has over 30 years’ experience in the field of genetics, personalized medicine, aging & longevity, with a documented track record as visionary scientist, inventor and business manager in academic, clinical and pharmaceutical environments across Europe and North America. Axel is the author of the “Blockchain & Healthcare Strategy Guide”, a ‘must-read’ for decision makers in the digital healthcare vertical. Axel is particularly well known for his work in epigenetics. He invented the first microarray technologies for epigenetic biomarker discovery, developed the ‘epigenetic theory of aging’ with his research leading to the worldwide first proof of whole genome epigenetic abnormalities in Alzheimer’s disease. Axel’s mission is to translate scientific discoveries into practical digital applications to help understand and prevent complex disorders, and to transform the way we age. He holds a Ph.D. in Human Genetics from the University of Cologne/Germany.

Recent Updates

View All

Shivom Roadmap_2019

Shivom Roadmap, Release Strategy & Status Update for 2019

Shivom Roadmap_2019

The march of time is relentless and as we start the second quarter of 2019, now is a good time to share some latest updates on Shivom’s roadmap, our evolving blockchain-based genomics & bio datahub and secure-storage and sharing platform, new partnerships and other developments pertaining to the Shivom ecosystem and OMX token.

Our Mission is Unchanged

The Shivom platform involves complex computer science and bioinformatics challenges. We aim to develop novel applications and a next-generation health information exchange and ecosystem which enables direct to consumer (“DTC”), pharma, clinical organizations, enterprises and others to provide customized health insights, therapies & care; and importantly to empower all individuals to own, manage and derive insights from their unique personal biodata in order to better manage their health and wellness. Collectively, we seek to work with all stakeholders to solve the various problems and inefficiencies the industry is facing at this period in time. If successful, our platform and technology solutions will not only lay the foundation for redefining the clinical research and drug discovery landscape but will also empower individuals to proactively manage their health and maintain control over their sensitive healthcare data. Ultimately, Shivom will be instrumental for helping to usher in a new era of precision medicine. Our mission remains unchanged.

MVP Release: Expected Features and Timeline

To deliver our vision, Shivom must hit key milestones and targets. The first key milestone is our MVP, which will demonstrate that data owners can securely store and share health and genomic and other “Omics” data; additionally, initiate an audit trail of data usage and activity based on our dynamic consent and permission features and traceability via the Ethereum blockchain. Enterprise customers such as pharmaceutical and institutional organisations will be able to search datasets based on various parameters, enter into a smart contract with data owners to utilize such data for clinical purposes and be able to run complex bioinformatic pipelines against big data without leaving Shivom’s platform. We remain confident in our abilities as researchers, engineers and operators to deliver on this milestone and key features as expected for our upcoming MVP release.  

We continue to scale up our development team in order to stay on track and reach our MVP milestone, which we plan to release by month-end June 2019. This version of our platform will include full traceability on blockchain, marketplace 2.0, end-to-end data discovery and analysis solution for enterprise customers and more. The requirements we have set include that it must clearly demonstrate traceability via Ethereum blockchain and enterprise customers running complex bioinformatic pipelines against big data without leaving the platform. From launch, the platform must be adaptive and be able to scale. Some features such as blockchain traceability, dynamic consent, updated user creation and login, however, will be offered in an interim release prior to the MVP. This next release will also include an updated marketplace with new products & services offered by our new DTC and telegenetic partners.

New Partners, Affiliates & Customers

Part of our roadmap will include onboarding of select DTC partners to be featured in our marketplace, which caters to consumers who wish to manage and improve their health and wellness within our blockchain- and token-based ecosystem. Our curated products will include select genetic and other testing kits, health reports, telemedicine services and more. For enterprise customers, our clinical platform will feature free and premium pipelines such as GWAS, Plink, Deep Variant and more. Additionally, researchers will have the ability to import their own pipelines from GitHub and in further updates following the MVP will be able to promote them in the marketplace and earn residual income through the use of our OMX tokens.

With these milestones in mind, this month we announced an exciting collaboration with Family Care Path (“FCP”), a spinoff company from world-renowned Cleveland Clinic. FCP maintains a genetic counsellor network and is offers proprietary web-based clinical decision support applications. The pilot for this collaboration will enable Shivom customers to access the FCP MyLegacy application and schedule a virtual genomic counselling session based on genomics and other personal healthcare and family data. We believe this service will be essential and provide much-needed guidance and clarity for our customers and are thrilled to be working with FCP, who are experts and thoughts leaders in the space. To read more about this collaboration visit the press release here.

We also onboarded Living DNA’s 3-in-1 Ancestry kit, which provides consumers with the ability to trace their origins back via maternal ancestors and see how they moved around the world over thousands of years. We are pleased to offer Living DNA as our first ancestry kit given the company’s scientific roots (the company is a collaboration of over 100 world-leading scientists, academic researchers and genetic experts from across the globe) and its relationship with DNA Worldwide Group, described as UK’s most advanced testing platform covering DNA, Drug, Alcohol and Forensic services. The company’s DNA kits are also based on a review of a significantly higher number of DNA markers then comparable lab testing companies; helping to ensure better results. As important, the company maintains strict privacy and security practices, which we require from all of our select partners and customers. To read more about this collaboration visit the press release here.

In addition to other D2C options, we are also working to onboard initial enterprise customers to include academic institutions and pharmaceutical companies. Given the requirements, our project is one of the more complex around the blockchain market today. Our task is difficult, but we are succeeding in our mission and progressing further every day. In parallel, we are also currently developing complementary projects with select partners that haven’t been announced as of yet. It is too early to release many details now but exciting things are happening both with respect to the kind of projects being pursued and the organizations now coalescing around the Shivom ecosystem.  Stay tuned to our Telegram announcements channel for further updates.

Shivom-Branded Products

You may have seen on our website and digital channels we announced our newest addition to our Shivom Innovation Council (“SIC”), Lion Martinez. Lion is a former national and European-level athlete, who has numerous national gold medals (in 100-metre sprint) in his kitty. He was also the youngest-ever Swedish to have participated in the 2002 European Championships in Munich. Lion holds a 100-metre world championship gold medal (2016) and has numerous records and medals (in 60, 100 and 200-metre sprints) to his credit. Additionally, he has been involved in coaching, public speaking and widespread health issues and initiatives over the past 20 years, engaging with children, youth, adults and senior citizens alike.

We are working closely with Lion and other stakeholders to develop an athletics/performance clinical program and other sports-related initiatives to include the development of Shivom-branded athletics products. The sports initiative in cooperation with our partners will use state-of-the-art genomics and analytics to develop insights catered to pro athletes in order to help make them fitter and perform on a higher level.  Our first product “The Complete Athletic Body Systems Report” will provide comprehensive performance related insights derived from multiple biological samples. We aim to unlock the secrets behind what makes an athlete … well, an athlete. We anticipate that our multi-part test will provide deep insights and help the pro user/elite athlete to better understand their body so that they can reach peak performance, reduce the risk of injury and recovery time, and more. Stay tuned for more information on our upcoming pro athletic products.

KuCoin & Exchange Updates

As some of you may be aware, our OMX token has been marked for special treatment on KuCoin for little over a month now. Despite our efforts and progress, trading volume remains low; accordingly, we are unlikely to meet Kucoin’s firm KPI requirement. Taking all factors into consideration to include our latest timelines and the increasingly limited support from the exchange, we have decided to focus our energies and resources on our existing and other prospective exchanges. Accordingly, we plan to pull out of KuCoin Exchange by 15 May 2019. Consequently, it’s imperative that all OMX holders with a balance/account in KuCoin plan accordingly and move their OMX token holdings to another appropriate exchange or secure wallet in a timely manner to avoid any potential complications. We highly recommend that any such individuals take appropriate action and transfer OMX holdings by 06 May 2019. Aside from KuCoin, OMX is currently traded on CoinBene, CoinSuper and IDEX. Our supported wallets include Jaax and Coinomi.


Announcements & Messaging Channels

On April 30th, we announced going live on Blockfolio Signals and Delta Direct. Our Director of Marketing and CEO will be providing updates on the project and token via these portfolio management applications along with our Telegram announcements channel. You may have well noticed we are in the process of moving away from our Telegram supergroup and pushing our active audience to our announcements channels, which will enable better, more targeted communications and excludes the numerous bots associated with the current supergroup. With this in mind and based on feedback received to date, we plan to phase out our supergroup in the coming months and ask our community members to join our new announcement channels in order to continue to get the latest project and token updates. We will give proper notice to our subscribers well in advance to ensure continuity of communications.

Looking Ahead

The next few months will be very exciting for the project. In addition to our scheduled MVP release, we have many other news and announcements to share as we continue to execute and focus on developing our applications & solutions and building the Shivom ecosystem. We look forward to keeping you updated on all and advancing the mission. As always, the entire Shivom team would like to thank everyone for their interest in the project, patience and continued belief in our team, technology and vision. We are also grateful for our early partners and their support and commitment to the project. As always, onwards and upwards!

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

Recent Updates

View All